News

Vinay Prasad, High-Risk Drugs and the FDA
U.S. Food and Drug Administration officials should encourage the thoughtful and careful evaluation of drugs.
Controversial FDA official Dr. Vinay Prasad departs agency
Dr. Vinay Prasad, the controversial critic of the US Food and Drug Administration who took a top role at the regulatory ...
Controversial vaccine official Dr. Vinay Prasad departs FDA
Dr. Vinay Prasad had been serving as the FDA's director of the Center for Biologics Evaluation and Research since May, and ...
Why Vinay Prasad Had to Go at FDA
The gene therapy chief wanted to block fast-track drug approvals.
US FDA's top vaccine official Vinay Prasad leaves agency after 3 months
The U.S. Food and Drug Administration's top vaccine official, Vinay Prasad, has left the agency after just three months as ...
FDA chief scientific officer Vinay Prasad resigns
Dr. Vinay Prasad, the chief scientific officer at the Food and Drug Administration, has resigned after only three months in ...
Vinay Prasad, controversial FDA official, abruptly departs agency
Prasad's exit ends a tumultuous tenure during which he led a reworking of agency guidelines on COVID vaccines and his office ...
COVID Response Critic Vinay Prasad Leaves FDA After Laura Loomer Attacks| RISING
Robby Soave and Niall Stanage discuss the unexpected ouster of one of the FDA's top regulators after receiving blowback from ...
FDA’s top vaccine official Vinay Prasad resigns after Loomer campaign against him
Vinay Prasad recently drew outrage from conservatives, including Laura Loomer, who disagreed with his approach to approving ...
US FDA's top vaccine official Vinay Prasad leaves agency after short stint
The U.S. Food and Drug Administration's top official, Vinay Prasad, has left the agency after nearly three months as Director ...
The Man Who Was Too MAHA for the Trump Administration
Vinay Prasad was supposed to be the guy who kept Big Pharma in check. Now he’s gone.
Big Pharma Demolishes Vinay Prasad for His Honesty
Prasad came to the Food & Drug Administration in May, hoping to set high, evidence-based standards for new medicines. He didn't even last three months. The industry's power has never been clearer.